Metformin Interdos Pharma

Metformin Hydrochloride, the active ingredient in Metformin Interdos Pharma, is a biguanide presented as an oral tablet for oral use. It lowers elevated blood glucose by improving insulin sensitivity and decreasing hepatic glucose production, and is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Metformin Interdos Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics, and health‑care systems, ensuring consistent quality and regulatory compliance across markets throughout globally.

Metformin Hydrochloride is used to improve glycemic control in the metabolic disorder of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves blood glucose control and reduces HbA1c levels. - Impaired glucose tolerance: delays progression to type 2 diabetes by enhancing insulin sensitivity. - Polycystic ovary syndrome: improves insulin resistance and may help regulate menstrual cycles.

Metformin Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Flatulence: increased intestinal gas. - Weight loss: mild reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening accumulation of lactate. - Severe hypoglycemia: may occur when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: long‑term use can reduce B12 absorption. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Skin reactions: severe rash or Stevens‑Johnson syndrome.

When prescribing Metformin Hydrochloride, clinicians should observe several safety considerations. - Renal function assessment: evaluate eGFR before initiation and periodically. - Monitor blood glucose: adjust therapy based on glycemic response. - Avoid in severe renal impairment: contraindicated when eGFR <30 mL/min/1.73 m². - Caution in hepatic disease: risk of lactic acidosis may increase. - Limit alcohol intake: excessive alcohol can precipitate lactic acidosis. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Metformin Hydrochloride has known drug interactions that may require dose adjustment or avoidance.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: may raise metformin plasma concentrations. - Alcohol excess: enhances risk of lactic acidosis. - Diuretics (loop or thiazide): may impair renal function, elevating metformin levels. - Nitrates: concurrent use can increase risk of hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors or ARBs: monitor renal function and potassium. - Sulfonylureas: increased risk of hypoglycemia when combined. - Digoxin: may require monitoring of serum levels. - Thyroid hormones: may affect glucose metabolism.